Transgène - Assemblée Générale des actionnaires du 22 mai 2019
Proxinvest attire l'attention des actionnaires sur différents points :
Tout d'abord les rémunérations attribuées et attribuables au Président Directeur Généraet Directeur Général Délégué manquent clairement de transparence. L'actionnaire ne peut pas appréhender l'exigence des rémunérations variables. (Résolutions 6 à 9)
Ensuite les conventions réglementées semblent désavantageuses pour les actionnaires minoritaires, ce qui entraine une recommandation de vote négative sur le rapport présenté en résolution 15.
Nous signalons l’élection de Mr Hedi Ben Brahim en remplacement de Mr Alain Mérieux, démissionnaire.
Le Comité d’Audit, d’après Proxinvest, n’est pas majoritairement indépendant (taux d'indépendance 50%).
Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.